Home/Pipeline/Budesonide MMX® (Uceris®)

Budesonide MMX® (Uceris®)

Ulcerative Colitis

MarketedCommercial

Key Facts

Indication

Ulcerative Colitis

Phase

Marketed

Status

Commercial

Company

Cosmo Pharmaceuticals

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals has successfully transitioned from an R&D-focused venture to a hybrid commercial organization with a mission to develop and commercialize innovative treatments for gastrointestinal diseases, dermatology, and colorectal cancer. Its core achievement is the proprietary MMX® technology, enabling targeted colonic drug delivery, which underpins its flagship products and pipeline. The company's strategy combines direct commercialization in key markets with strategic out-licensing and partnerships to maximize global reach and capital efficiency while advancing a pipeline of novel GI and dermatology assets.

View full company profile

Therapeutic Areas

Gastroenterology Dermatology

Other Ulcerative Colitis Drugs

Drug	Company	Phase	Status
PALI-2108	Palisade Bio	Phase 2	Advancing towards initiation
ALTB-268	AltruBio	Phase IIa	Active
AIM-HI-UC	PathAI	Clinical Trials	Active
Patient Stratification in Ulcerative Colitis	Enable Medicine	Research	Active
Mesalazine (Lifecycle Management)	Dr. Falk Pharma	Approved/Phase 3	Active
AhR Agonist Program	Azora Therapeutics	Phase 1b	Active
R-3750	Virtici	Phase 1	Active
GPR35 Inhibitor	ThirtyFiveBio	Preclinical	Active
BT-600	Biora Therapeutics	Phase 1	Active
Asacol® (mesalazine)	Tillotts Pharma	Approved	Active
MB310	Microbiotica	Phase 1b	Active
'1805	Revolo Biotherapeutics	Phase 2 (Planned)	Active